NCT06996730: A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
- State
- Under way
- Phase
- Phase 2 and Phase 3
- People
- 240 planned
- Started
- 8 Jul 2026
- Primary completion
- 1 Jun 2030
- Arms
- Part 2: RG6289 plus donanemab
- Results
- None posted
- 30 May 2025: Trial registered
- 8 Jul 2026: Trial started